CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
Guido Ghilardi(Hospital of the University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Jakub Svoboda(UPMC Hillman Cancer Center), Elise A. Chong(Hospital of the University of Pennsylvania), Peter Brændstrup(Zealand University Hospital), Stephen J. Schuster(Hospital of the University of Pennsylvania)
Cited by 36
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523